Regulatory & PolicyAs Medicare prepares to offer GLP-1 drugs like Wegovy and Zepbound to older adults for $50 a month beginning in July, the agency remains silent on how this program will impact taxpayer costs. Simultaneously, Massachusetts has filed a lawsuit against United Healthcare, escalating healthcare coverage tensions in the state. These developments highlight the complex interplay between federal drug coverage policies and state-level healthcare regulatory actions.
Emily Carter·Jun 1, 2026
Healthcare InvestmentOral health is increasingly recognized as intrinsic to overall health, especially in pregnant women. This article explores the compelling reasons why obstetricians and gynecologists, public health agencies, and insurance plans should intensify their focus on oral health to reduce pregnancy complications such as pre-eclampsia.
Emily Carter·Jun 1, 2026 
Healthcare InvestmentThe glucose monitoring technology initially designed for diabetes care is increasingly being adapted for broader health applications. Signos’ recent $20 million investment round underscores the expanding role of CGM in personalized health, especially focusing on weight management through real-time glucose data and lifestyle recommendations.
Emily Carter·Jun 1, 2026 
Healthcare InvestmentThe health tech sector continues its trajectory of growth with major funding announcements. These investments will support the development of transformative technologies poised to enhance care delivery, improve patient outcomes, and drive healthcare efficiency worldwide.
Emily Carter·May 31, 2026 
Regulatory & PolicyAfter two FDA rejections and recent leadership changes at the agency, Replimune is making a renewed effort to secure approval for its cancer immunotherapy drug RP1. This analysis examines the context and potential implications of this resubmission.
Emily Carter·May 29, 2026 
Medical TechnologyThe collaboration between industry leaders Walmart and Teladoc Health represents a significant step forward in expanding virtual healthcare access across the United States. This partnership leverages Walmart's extensive retail footprint and Teladoc’s virtual care expertise to meet growing patient demands for convenient and accessible healthcare solutions.
Emily Carter·May 29, 2026 
Regulatory & PolicyIn a move that underscores the evolving nature of the COVID-19 pandemic response, the FDA has assembled a panel of vaccine experts to reevaluate and update the seasonal COVID-19 vaccine formulation. This development comes in the context of significant changes to vaccine advisory committees following recent political and health sector shifts.
Emily Carter·May 27, 2026 
Biopharmaceutical IndustryEli Lilly’s remarkable performance in innovation and invention, as recognized by IDEA Pharma, offers a compelling case study on how strategic investments and regulatory successes can elevate a pharmaceutical company to industry leadership. This analysis explores the factors behind Lilly’s success and its implications for the broader biopharmaceutical sector.
Emily Carter·May 26, 2026 
Medical TechnologyArtificial intelligence has emerged as a revolutionary tool in healthcare, positioned to serve as the new entry point for patient engagement. Yet, for this potential to be realized broadly, accessibility must be prioritized during AI system design and deployment. This analysis delves into the current obstacles blocking equitable access and discusses the implications for healthcare providers and patients alike.
Emily Carter·May 24, 2026 
Regulatory & PolicyThe appeal from Takeda raises significant issues about pharmaceutical patent practices, generic drug market entry, and antitrust enforcement. This case underscores ongoing tensions over balancing innovation incentives with affordable access.
Emily Carter·May 23, 2026 
Regulatory & PolicyPersistent vacancies in key NIH leadership positions underscore challenges in agency governance and could affect health policy outcomes and research directions. The broader impact reverberates through related health agencies amid political and operational uncertainty.
Emily Carter·May 20, 2026 
Regulatory & PolicyThe suppression of doctors’ voices on social media platforms by hospitals and health systems is raising alarms among experts who warn it fuels health misinformation. This post explores the intricacies behind these policies, the implications for public health, and the urgent need to empower medical professionals to combat false information effectively online.
Emily Carter·May 13, 2026 